TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28612995

Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM)
Number of subjects: 5

Group type: COMPARATOR
Intervention: In-clinic follow-up
Number of subjects: 5
Study: 26304464

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.0 g/day)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2.0 g/day)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 23695657

Group type: EXPERIMENTAL
Intervention: 10 mg Lutein, 1 mg Zeaxanthin, 100 mg DHA, 30 mg EPA, antioxidants (D1)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 10 mg Lutein, 1 mg Zeaxanthin, 100 mg DHA, 30 mg EPA, antioxidants (D2)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 172
Study: 21270185

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg/day or 100 mg/day)
Number of subjects: 2523

Group type: COMPARATOR
Intervention: Nonaspirin
Number of subjects: 2523
Study: 19922256

Group type: EXPERIMENTAL
Intervention: Mud therapy (topical gel prepared using Lake Urmia mud)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23141953

Group type: COMPARATOR
Intervention: Cervical artificial insemination (CAI): 3×10(9) spermatozoa/80 ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-cervical artificial insemination (post-CAI 1): 1.5×10(9) spermatozoa/40 ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-cervical artificial insemination (post-CAI 2): 1×10(9) spermatozoa/26 ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cervical artificial insemination (CAI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-cervical artificial insemination (post-CAI 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-cervical artificial insemination (post-CAI 2)
Number of subjects: 0
Study: 15765197

Group type: EXPERIMENTAL
Intervention: Progressive exercise program (mainly resistance training) for six months
Number of subjects: 95

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 95
Study: 12538174

Group type: EXPERIMENTAL
Intervention: BIS 50 (BIS level 45-55)
Number of subjects: 62

Group type: COMPARATOR
Intervention: BIS 40 (BIS level 35-45)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: BIS 50
Number of subjects: 62

Group type: COMPARATOR
Intervention: BIS 40
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 9819168

Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP: 2 mg.kg(‐1) body weight)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PL: maltodextrin capsule)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 7
Study: 8583101

Group type: EXPERIMENTAL
Intervention: 5-ASA (Claversal), 0.5 g b.i.d.
Number of subjects: 88

Group type: COMPARATOR
Intervention: SASP, 1 g b.i.d.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 5-ASA and SASP
Number of subjects: 88
Study: 2642669

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate 750 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 60
Study: 791307

Group type: EXPERIMENTAL
Intervention: suxamethonium 100 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: suxethonium 150 mg
Number of subjects: 75
Study: 11589838

Group type: EXPERIMENTAL
Intervention: Troponin T determinations
Number of subjects: 856

Group type: COMPARATOR
Intervention: Standard evaluation (controls)
Number of subjects: 856
Study: 30904248

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous acetaminophen
Number of subjects: 0
Study: 30256548

Group type: EXPERIMENTAL
Intervention: Panic-focused psychodynamic psychotherapy
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Applied relaxation training
Number of subjects: 116
Study: 26254169

Group type: COMPARATOR
Intervention: BCS (Breast-Conserving Surgery)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: BCS + M (BCS with resection of 5 additional margins)
Number of subjects: 75

Group type: COMPARATOR
Intervention: BCS
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: BCS + M
Number of subjects: 75
Study: 24219842

Group type: EXPERIMENTAL
Intervention: PACCI-ED (intervention group)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (blinded to PACCI-ED responses)
Number of subjects: 77
Study: 22496082

Group type: EXPERIMENTAL
Intervention: Complete revascularization (RMJI=0)
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Mildly incomplete revascularization (RMJI >0≤33)
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Moderately to severely incomplete revascularization (RMJI >33)
Number of subjects: 751
Study: 20297858

Group type: EXPERIMENTAL
Intervention: OROS® hydromorphone administered once daily for up to 52 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OROS® hydromorphone
Number of subjects: 0
Study: 18607594

Group type: EXPERIMENTAL
Intervention: 1.0 M gadobutrol
Number of subjects: 471

Group type: COMPARATOR
Intervention: 0.5 M gadopentate dimeglumine
Number of subjects: 471
Study: 15814078

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment program for anxiety disorder (12-week duration)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 23
Study: 11923558

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine capsule (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 12
Study: 9459251

Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (5 mg) with intraarticular bupivacaine (30 mL of 0.25%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (5 mg) with normal saline (30 mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intraarticular bupivacaine (30 mL of 0.25%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intraarticular bupivacaine (30 mL of 0.25%) with intravenous morphine (5 mg)
Number of subjects: 100
Study: 8583231

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied to frontal or parietal cortex, timing at -70 msec and -20 msec before saccade onset.
Number of subjects: 0
Study: 2523769

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.4 nmol min‐1 kg‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Colour word conflict test (CWT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 16
Study: 795013

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tetracycline HCI
Number of subjects: 36
Study: 30580563

Group type: EXPERIMENTAL
Intervention: Elevated serum Dkk‐1 levels
Number of subjects: 3178

Group type: EXPERIMENTAL
Intervention: Each SD increase of log-transformed Dkk‐1
Number of subjects: 3178

Group type: EXPERIMENTAL
Intervention: Serum Dkk‐1 addition to conventional risk factors
Number of subjects: 3178
Study: 28426885

Group type: EXPERIMENTAL
Intervention: CRT-ON
Number of subjects: 755

Group type: COMPARATOR
Intervention: CRT-OFF
Number of subjects: 755
Study: 25284643

Group type: EXPERIMENTAL
Intervention: Nucleus(®) 6 SCAN (activating SNR‐NR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nucleus(®) 6 SCAN
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nucleus(®) 6 and Nucleus(®) 5
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nucleus(®) 5 to Nucleus(®) 6 conversion
Number of subjects: 30
Study: 23743714

Group type: EXPERIMENTAL
Intervention: Dangerous graspable objects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral graspable objects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ungraspable objects (both dangerous and neutral)
Number of subjects: 0
Study: 21272338

Group type: EXPERIMENTAL
Intervention: RENEW (resistance exercise via negative eccentrically-induced work) for 12 weeks
Number of subjects: 40
Study: 19218125

Group type: EXPERIMENTAL
Intervention: Prefilled pen
Number of subjects: 184

Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 184
Study: 16968715

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly and 25 mg twice weekly
Number of subjects: 356
Study: 14618054

Group type: EXPERIMENTAL
Intervention: Curved shaft catheters (2 new and 1 standard)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Straight shaft catheters
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination of curved and straight shaft catheters
Number of subjects: 29
Study: 10753829

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (3 microg/kg, single bolus subcutaneous injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF
Number of subjects: 0
Study: 8795757

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not on CCB)
Number of subjects: 83
Study: 1617888

Group type: EXPERIMENTAL
Intervention: Surfactant replacement therapy
Number of subjects: 0
Study: 6235685

Group type: EXPERIMENTAL
Intervention: spectinomycin
Number of subjects: 176

Group type: COMPARATOR
Intervention: penicillin G
Number of subjects: 176
Study: 30772471

Group type: EXPERIMENTAL
Intervention: Integrated asthma community health workers (CHW) home visits
Number of subjects: 223

Group type: COMPARATOR
Intervention: Certified asthma educator (AE‐C) education in the clinic
Number of subjects: 223
Study: 29889057

Group type: EXPERIMENTAL
Intervention: Assisted sit-up exercise (SUE) using HubEX-LEX®
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional core stabilization exercise (CSE)
Number of subjects: 36
Study: 27341795

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (CBP group, n=48)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Paclitaxel plus nedaplatin (NDP group, n=46)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Duration of chemotherapy
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Chemotherapy scheme
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Age and pathological type
Number of subjects: 94
Study: 23676337

Group type: EXPERIMENTAL
Intervention: 3-month Internet-based intervention promoting physical activity
Number of subjects: 536
Study: 22907974

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m² i.v. for 100 minutes on days 1, 8, and 15 of a 28-day cycle)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gemcitabine plus Docetaxel (Gemcitabine 900 mg/m² i.v. for 90 minutes on days 1 and 8, plus Docetaxel 100 mg/m² i.v. for 1 hour on day 8 of a 21-day cycle with lenograstim)
Number of subjects: 90
Study: 20081039

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg three times per day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg three times per day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All treatment arms (gabapentin and placebo)
Number of subjects: 80
Study: 18076806

Group type: EXPERIMENTAL
Intervention: Gemcitabine with concurrent radiotherapy (400 mg/m(2) weekly, total radiotherapy dose of 60-66 Gy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiotherapy alone (total dose of 60-66 Gy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Gemcitabine with concurrent radiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 60
Study: 15960096

Group type: EXPERIMENTAL
Intervention: Earplugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Earmuffs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double hearing protection (earplugs and earmuffs simultaneously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No hearing protection
Number of subjects: 0

Group type: COMPARATOR
Intervention: No auditory cue (control condition)
Number of subjects: 0
Study: 12131602

Group type: EXPERIMENTAL
Intervention: Kava kava (Piper methysticum)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 10474848

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy (CBT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: No-therapy control group
Number of subjects: 124
Study: 8942598

Group type: EXPERIMENTAL
Intervention: Modified BronchoCath double-lumen tube (DLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Univent tube with bronchial blocker
Number of subjects: 40
Study: 1757243

Group type: EXPERIMENTAL
Intervention: 60 mg pyridostigmine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 30 mg pyridostigmine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 6126145

Group type: EXPERIMENTAL
Intervention: 4% intranasal sodium cromoglycate solution
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 47
Study: 31634258

Group type: EXPERIMENTAL
Intervention: Preoperative educational video on MMS in addition to traditional informed consent
Number of subjects: 231

Group type: COMPARATOR
Intervention: Informed consent without video viewing (Control)
Number of subjects: 231
Study: 29803404

Group type: EXPERIMENTAL
Intervention: Motor Unit Number Index (MUNIX) measurement
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: MUNIX
Number of subjects: 36
Study: 26084276

Group type: EXPERIMENTAL
Intervention: Miglustat 100 mg t.i.d. + S. boulardii 500 mg b.i.d.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Miglustat 100 mg t.i.d. + placebo
Number of subjects: 42
Study: 23351522

Group type: EXPERIMENTAL
Intervention: Sertraline and Olanzapine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sertraline and Placebo
Number of subjects: 100
Study: 20638899

Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 332
Study: 18259972

Group type: EXPERIMENTAL
Intervention: Arformoterol 15 micro g BID
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Arformoterol 25 micro g BID
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Arformoterol 50 micro g QD
Number of subjects: 1456

Group type: EXPERIMENTAL
Intervention: Salmeterol 42 micro g BID
Number of subjects: 1456

Group type: COMPARATOR
Intervention: Arformoterol
Number of subjects: 1456

Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 1456

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1456
Study: 16806442

Group type: EXPERIMENTAL
Intervention: Transperitoneal pelvic lymphadenectomy (TPL)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Extraperitoneal pelvic lymphadenectomy (EPL)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Laparoscopic pelvic lymphadenectomy (LPL)
Number of subjects: 168
Study: 15636035

Group type: EXPERIMENTAL
Intervention: Parecoxib preoperatively (40 mg IM/IV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Parecoxib postoperatively (40 mg IM/IV)
Number of subjects: 80
Study: 10862371

Group type: EXPERIMENTAL
Intervention: Prayer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 9165581

Group type: EXPERIMENTAL
Intervention: 560 mg estramustine phosphate (EMP) per day
Number of subjects: 197

Group type: COMPARATOR
Intervention: 3 mg diethylstilbestrol (DES) per day
Number of subjects: 197
Study: 8109834

Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiinflammatory drugs (NSAIDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital subtraction radiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Further studies
Number of subjects: 0
Study: 3897460

Group type: EXPERIMENTAL
Intervention: High-dose lecithin (20-25 g/day of purified soya lecithin for six months)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 2903827

Group type: EXPERIMENTAL
Intervention: Intravenous dosing of xamoterol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral dosing of xamoterol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison of pharmacokinetics in cardiac failure patients vs young healthy male volunteers
Number of subjects: 8
Study: 31353758

Group type: EXPERIMENTAL
Intervention: tSMS over the left auditory cortex
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: tSMS over the right auditory cortex
Number of subjects: 15
Study: 29299661

Group type: EXPERIMENTAL
Intervention: TVT-EXACT (TVT-E)
Number of subjects: 125

Group type: COMPARATOR
Intervention: TVT-ABBREVO (TVT-A)
Number of subjects: 125
Study: 27237709

Group type: EXPERIMENTAL
Intervention: Ferric maltol 30 mg b.d. for 52 weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo (initial treatment)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ferric maltol treatment
Number of subjects: 111
Study: 24636040

Group type: EXPERIMENTAL
Intervention: Oseltamivir 2.5 mg (pilot low dose determination study)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oseltamivir 35 mg (single-dose PK study)
Number of subjects: 14
Study: 23276888

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) with oral calcium and vitamin D supplementation
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (oral calcium and vitamin D supplementation only)
Number of subjects: 74
Study: 20451546

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.05, 0.1, 0.25, 0.5 and 1mg at 15min intervals)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17655781

Group type: EXPERIMENTAL
Intervention: Physostigmine (30 µg kg-1)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 211
Study: 16868708

Group type: EXPERIMENTAL
Intervention: CyA, MMF, Steroids and Basiliximab (Group A)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tacrolimus, MMF, Steroids and Daclizumab (Group B)
Number of subjects: 26
Study: 15178717

Group type: EXPERIMENTAL
Intervention: 25,000 IU/mL r‐UK
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 15,000 IU/mL r‐UK
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 5,000 IU/mL r‐UK
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 11102257

Group type: EXPERIMENTAL
Intervention: Intracoronary beta-brachytherapy (90Sr/90Y source)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (non-irradiated)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low-dose subsegments (<6 Gy)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Effective-dose subsegments (>=6 Gy)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-irradiated subsegments
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Irradiated subsegments
Number of subjects: 31
Study: 9316529

Group type: EXPERIMENTAL
Intervention: Metoprolol (maximal dose 50 mg three times daily for 6 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Milrinone (5 to 10 micrograms/kg body weight per min)
Number of subjects: 15
Study: 8450459

Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg/70 kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg/70 kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg/70 kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Triazolam (0.75 mg/70 kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg/70 kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg/70 kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lorazepam (4 mg/70 kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lorazepam (6 mg/70 kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (0 mg for both drugs)
Number of subjects: 8
Study: 3536530

Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 18
Study: 30832692

Group type: EXPERIMENTAL
Intervention: Downregulation of RNF128
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RNF128 interference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low RNF128 expression
Number of subjects: 0
Study: 29239943

Group type: EXPERIMENTAL
Intervention: EEG-guided anesthesia
Number of subjects: 117
Study: 27394195

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 4262

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 4262
Study: 24818523

Group type: EXPERIMENTAL
Intervention: banked human milk plus 5% commercial fortifier with bovine protein
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: banked human milk plus evaporated fortifier derived from modified human milk
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: banked human milk plus lyophilized fortifier derived from modified human milk
Number of subjects: 24
Study: 22870238

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg daily)
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Multi-nutrients without zinc
Number of subjects: 612

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 612
Study: 20420586

Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015% eye drops
Number of subjects: 533

Group type: COMPARATOR
Intervention: Latanoprost 0.005% eye drops
Number of subjects: 533
Study: 18528875

Group type: EXPERIMENTAL
Intervention: Dissonance-based thin-ideal internalization reduction program
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Healthy weight management program
Number of subjects: 481

Group type: COMPARATOR
Intervention: Expressive-writing control condition
Number of subjects: 481

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 481
Study: 16046689

Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging smoking cessation programme
Number of subjects: 1705

Group type: COMPARATOR
Intervention: Control group (no text messaging until six months)
Number of subjects: 1705
Study: 11891670

Group type: EXPERIMENTAL
Intervention: S-verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R-verapamil
Number of subjects: 0
Study: 10618615

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Thermoradiotherapy (TRT) with 3 sessions of hyperthermia plus RT
Number of subjects: 37